Search Results

You are looking at 1 - 10 of 10 items for :

  • "iron chelation therapy" x
  • Refine by Access: All x
Clear All
Full access

David P. Steensma

chelation therapy among patients with iron overload in MDS Identify adverse events associated with oral iron chelation therapy M ore than 90% of patients with myelodysplastic syndromes (MDS) are anemic at the time of diagnosis, 1 and most patients will

Full access

Peter L. Greenberg

MJ Bowen DT . Oxidative stress and the myelodysplastic syndromes . Int J Hematol 2003 ; 77 : 342 – 350 . 8. Gotlib J Greenberg P . Supportive care in myelodysplastic syndrome: hemopoietic cytokines and iron chelation therapy . In

Full access

Peter L. Greenberg, Cynthia K. Rigsby, Richard M. Stone, H. Joachim Deeg, Steven D. Gore, Michael M. Millenson, Stephen D. Nimer, Margaret R. O'Donnell, Paul J. Shami, and Rashmi Kumar

; 2 : 27 – 30 . 4 Hershko CM Link GM Konijn AM Cabantchik ZI . Iron chelation therapy . Curr Hematol Rep 2005 ; 4 : 110 – 116 . 5 Olivieri NF Brittenham GM . Iron-chelating therapy and the treatment of thalassemia . Blood

Full access

Peter L. Greenberg, Leon E. Cosler, Salvatore A. Ferro, and Gary H. Lyman

granulocyte colony-stimulating factor in combination with erythropoietin . Blood 1993 ; 82 : 737 – 743 . 7. Gotlib J Greenberg PL . Supportive care in myelodysplastic syndromes: hemopoietic cytokine and iron chelation therapy . In: Greenberg PL

Full access

Peter L. Greenberg, Eyal Attar, John M. Bennett, Clara D. Bloomfield, Carlos M. De Castro, H. Joachim Deeg, James M. Foran, Karin Gaensler, Guillermo Garcia-Manero, Steven D. Gore, David Head, Rami Komrokji, Lori J. Maness, Michael Millenson, Stephen D. Nimer, Margaret R. O'Donnell, Mark A. Schroeder, Paul J. Shami, Richard M. Stone, James E. Thompson, and Peter Westervelt

overload states (e.g., thalassemia) using iron chelation therapy has been shown in patients in whom the most effective chelation occurred. 43 , 47 This included transfusion independence in a portion of a small group of carefully studied patients with MDS

Full access

Brady L. Stein, Jason Gotlib, Murat Arcasoy, Marie Huong Nguyen, Neil Shah, Alison Moliterno, Catriona Jamieson, Daniel A. Pollyea, Bart Scott, Martha Wadleigh, Ross Levine, Rami Komrokji, Rebecca Klisovic, Krishna Gundabolu, Patricia Kropf, Meir Wetzler, Stephen T. Oh, Raul Ribeiro, Rita Paschal, Sanjay Mohan, Nikolai Podoltsev, Josef Prchal, Moshe Talpaz, David Snyder, Srdan Verstovsek, and Ruben A. Mesa

-associated anemia . Leuk Res 2013 ; 37 : 1429 – 1431 . 89. Elli EM Belotti A Aroldi A . Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis . Mediterr J Hematol Infect Dis 2014 ; 6 : e2014042

Full access

)–free survival. Iron chelation therapy (ICT) may improve patient survival and quality of life. Deferasirox (DFX) is an oral chelator for the treatment of iron overload in patients with MDS. Methods: This retrospective cohort study used 100% Medicare claims data

Full access

Peter L. Greenberg, Richard M. Stone, Aref Al-Kali, Stefan K. Barta, Rafael Bejar, John M. Bennett, Hetty Carraway, Carlos M. De Castro, H. Joachim Deeg, Amy E. DeZern, Amir T. Fathi, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Elizabeth A. Griffiths, David Head, Ruth Horsfall, Robert A. Johnson, Mark Juckett, Virginia M. Klimek, Rami Komrokji, Lisa A. Kujawski, Lori J. Maness, Margaret R. O'Donnell, Daniel A. Pollyea, Paul J. Shami, Brady L. Stein, Alison R. Walker, Peter Westervelt, Amer Zeidan, Dorothy A. Shead, and Courtney Smith

, iron chelation therapy, and/or ESAs. The 2-year cumulative incidence of AML progression was 7% with lenalidomide and 12% in the untreated cohort, and corresponding 5-year rates were 23% and 20%, respectively; median time to AML progression had not been

Full access

Peter L. Greenberg, Eyal Attar, John M. Bennett, Clara D. Bloomfield, Uma Borate, Carlos M. De Castro, H. Joachim Deeg, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Steven D. Gore, David Head, Rami Komrokji, Lori J. Maness, Michael Millenson, Margaret R. O’Donnell, Paul J. Shami, Brady L. Stein, Richard M. Stone, James E. Thompson, Peter Westervelt, Benton Wheeler, Dorothy A. Shead, and Maoko Naganuma

patients in a multicenter registry; n=125) in patients with IPSS low-/INT-1-risk MDS with del(5q) RBC transfusion-dependent anemia. 133 Untreated patients from the registry had received best supportive care, including RBC transfusion, iron chelation

Full access

demonstrating the survival benefits of iron chelation therapy (ICT), NCCN Guidelines for MDS recommend ICT for patients with International Prognostic Scoring System (IPSS) low- to intermediate-1–risk MDS and potential transplant candidates. Methods: Best